MarÃ-a D Lozano,, Miac

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5648610/publications.pdf

Version: 2024-02-01

103 papers 4,275 citations

35 h-index 62 g-index

108 all docs

 $\frac{108}{\text{docs citations}}$

108 times ranked 7284 citing authors

#	Article	IF	CITATIONS
1	COVIDâ€19 pandemic impact on cytopathology practice in the postâ€lockdown period: An international, multicenter study. Cancer Cytopathology, 2022, 130, 344-351.	2.4	15
2	Recommendations for optimizing the use of cytology in the diagnosis and management of patients with lung cancer. Revista Espanola De Patologia, 2022, , .	0.2	1
3	Evaluation of the role of thyroid scintigraphy in the differential diagnosis of thyrotoxicosis. Clinical Endocrinology, 2021, 94, 466-472.	2.4	6
4	Diagnostic accuracy of visual analysis versus dual time-point imaging with 18F-FDG PET/CT for the characterization of indeterminate pulmonary nodules with low uptake. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 155-160.	0.2	5
5	Molecular biomarkers in early stage lung cancer. Translational Lung Cancer Research, 2021, 10, 1165-1185.	2.8	23
6	Challenges of ICC and FISH in the Field of Targeted Therapies from Cell Block to Smears. Journal of Molecular Pathology, 2021, 2, 55-65.	1.2	1
7	Utilisation of cytological samples for multiplex immunofluorescence assay. Cytopathology, 2021, 32, 611-616.	0.7	4
8	PD-L1 in Cytological Samples: A Review and a Practical Approach. Frontiers in Medicine, 2021, 8, 668612.	2.6	17
9	A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer. Translational Research, 2021, 233, 77-91.	5. 0	15
10	Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on <scp>IL</scp> â€8. Journal of Pathology, 2021, 255, 190-201.	4.5	49
11	Characterization of Newly Detected Costal Pleura–attached Noncalcified Nodules at Annual Low-Dose CT Screenings. Radiology, 2021, 301, 724-731.	7.3	10
12	The importance of low-dose CT screening to identify emphysema in asymptomatic participants with and without a prior diagnosis of COPD. Clinical Imaging, 2021, 78, 136-141.	1.5	18
13	A comprehensive diagnosis of a desmoplastic small round cell tumor of unusual location based on fineâeneedle aspiration cytology: Report of a case arising in the parotid gland and review of the literature. Diagnostic Cytopathology, 2020, 48, 827-832.	1.0	5
14	Global impact of the COVIDâ€19 pandemic on cytopathology practice: Results from an international survey of laboratories in 23 countries. Cancer Cytopathology, 2020, 128, 885-894.	2.4	47
15	The role of cytopathology practice and research in the development of personalized medicine in Iberoamerica. Diagnostic Cytopathology, 2020, 48, 819-820.	1.0	O
16	Diverse immune environments in human lung tuberculosis granulomas assessed by quantitative multiplexed immunofluorescence. Modern Pathology, 2020, 33, 2507-2519.	5 . 5	32
17	Towards the elimination of hepatitis C: implementation of reflex testing in Andalusia. Revista Espanola De Enfermedades Digestivas, 2020, 112, 515-519.	0.3	8
18	Programmed death–ligand 1 expression on direct Papâ€stained cytology smears from non–small cell lung cancer: Comparison with cell blocks and surgical resection specimens. Cancer Cytopathology, 2019, 127, 470-480.	2.4	31

#	Article	IF	CITATIONS
19	Assessment of a New ROS1 Immunohistochemistry CloneÂ(SP384)Âfor the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study. Journal of Thoracic Oncology, 2019, 14, 2120-2132.	1.1	48
20	EUS-guided tissue acquisition in the study of the adrenal glands: Results of a nationwide multicenter study. PLoS ONE, 2019, 14, e0216658.	2.5	13
21	Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling. PLoS ONE, 2019, 14, e0215970.	2.5	3
22	Consistency and reproducibility of nextâ€generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. Cancer Cytopathology, 2019, 127, 285-296.	2.4	39
23	Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clinical Cancer Research, 2019, 25, 4663-4673.	7.0	210
24	Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer. International Journal of Cancer, 2019, 145, 1991-2001.	5.1	32
25	Survival with Parenchymal and Pleural Invasion of Non–Small Cell Lung Cancers Less than 30 mm. Journal of Thoracic Oncology, 2019, 14, 890-902.	1.1	25
26	Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria. Medicine (United States), 2019, 98, e16509.	1.0	6
27	TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients. Journal of Clinical Medicine, 2019, 8, 2134.	2.4	17
28	Gastrointestinal Endoscopic Ultrasoundâ€Guided Fineâ€Needle Aspiration for Assessing Suspected Deep Pelvic or Abdominal Recurrence in Gynecologic Cancer: A Feasibility Study. Journal of Ultrasound in Medicine, 2019, 38, 761-765.	1.7	4
29	CT screening for lung cancer: comparison of three baseline screening protocols. European Radiology, 2019, 29, 5217-5226.	4.5	11
30	Metastatic tumors in the pancreas: the role of endoscopic ultrasound-guided fine-needle aspiration. Revista Espanola De Enfermedades Digestivas, 2019, 111, 345-350.	0.3	6
31	Incidental lesions of the pancreas. A clinicopathological study of 100 cases surgically treated. Revista Espanola De Enfermedades Digestivas, 2019, 112, 85-89.	0.3	4
32	Cytology Smears in the Era of Molecular Biomarkers in Non–Small Cell Lung Cancer: Doing More With Less. Archives of Pathology and Laboratory Medicine, 2018, 142, 291-298.	2.5	60
33	Detection of EGFR Variants in Plasma. Journal of Molecular Diagnostics, 2018, 20, 483-494.	2.8	37
34	P1.09-09 Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients. Journal of Thoracic Oncology, 2018, 13, S553-S554.	1.1	0
35	Complement C4d-specific antibodies for the diagnosis of lung cancer. Oncotarget, 2018, 9, 6346-6355.	1.8	39
36	Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer. Cancer Medicine, 2018, 7, 3474-3483.	2.8	11

#	Article	IF	Citations
37	A novel proteinâ€based prognostic signature improves risk stratification to guide clinical management in earlyâ€stage lung adenocarcinoma patients. Journal of Pathology, 2018, 245, 421-432.	4.5	29
38	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respiratory Medicine, the, 2018, 6, 771-781.	10.7	167
39	ALK and ROS1 testing on lung cancer cytologic samples: Perspectives. Cancer Cytopathology, 2017, 125, 817-830.	2.4	44
40	Consistency and reproducibility of nextâ€generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathology, 2017, 125, 615-626.	2.4	58
41	In patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockers. Annals of Oncology, 2017, 28, xi5.	1.2	2
42	Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value. Tumor Biology, 2016, 37, 13687-13694.	1.8	37
43	Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT. Lung Cancer, 2016, 97, 81-86.	2.0	34
44	Dual modulation of MCL-1 and mTOR determines the response to sunitinib. Journal of Clinical Investigation, 2016, 127, 153-168.	8.2	49
45	Assessment of EGFR and KRAS mutation status from FNAs and coreâ€needle biopsies of nonâ€small cell lung cancer. Cancer Cytopathology, 2015, 123, 230-236.	2.4	25
46	Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma. European Journal of Dermatology, 2015, 25, 392-403.	0.6	12
47	Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. BMC Genomics, 2015, 16, 752.	2.8	12
48	Teacher change: ideas emerging from a project for the teaching of university mathematics. Teaching in Higher Education, 2015, 20, 699-710.	2.6	3
49	Cribado de cÃ;ncer de pulmón: catorce años de experiencia del Programa Internacional de Detección Precoz de CÃ;ncer de Pulmón con TBDR de Pamplona (P-IELCAP). Archivos De Bronconeumologia, 2015, 51, 169-176.	0.8	59
50	Lung Cancer Screening: Fourteen Year Experience of the Pamplona Early Detection Program (P-IELCAP). Archivos De Bronconeumologia, 2015, 51, 169-176.	0.8	28
51	Functional expression of CD137 (4-1BB) on T helper follicular cells. Oncolmmunology, 2015, 4, e1054597.	4.6	15
52	Variations in Molecular Profile in NSCLC Can Be Analyzed Using Cytological Samples. International Journal of Surgical Pathology, 2015, 23, 111-115.	0.8	10
53	Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors. Clinical Chemistry, 2015, 61, 297-304.	3.2	221
54	Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer. PLoS ONE, 2015, 10, e0119878.	2.5	23

#	Article	IF	CITATIONS
55	Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma. PLoS ONE, 2014, 9, e86263.	2.5	76
56	Antitumor effects of a monoclonal antibody to human CCR9 in leukemia cell xenografts. MAbs, 2014, 6, 1000-1012.	5.2	31
57	Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clinica Chimica Acta, 2014, 429, 168-174.	1.1	20
58	Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2058-2065.	6.4	75
59	Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2014, 16, 362-373.	2.4	7
60	Integrated genomic analysis for revealing broad remodeling of EGFR-targeted therapy resistant lung cancers Journal of Clinical Oncology, 2014, 32, 8083-8083.	1.6	O
61	Abstract 954: Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer patients with acquired resistance to erlotinib. , 2014, , .		O
62	Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy. Journal of Translational Medicine, 2013, 11, 13.	4.4	38
63	Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. Journal of the National Cancer Institute, 2013, 105, 1385-1393.	6.3	127
64	MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. Modern Pathology, 2013, 26, 171-181.	5.5	19
65	Spinal meningioma diagnosis based on transesophageal endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). Revista Espanola De Enfermedades Digestivas, 2013, 105, 500-501.	0.3	O
66	Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung. Journal of Clinical Oncology, 2012, 30, 1129-1136.	1.6	63
67	Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Melanoma (MEL). Annals of Oncology, 2012, 23, ix361.	1.2	10
68	Feasibility and Usefulness of Determining EGFR and KRAS Mutations in Cytological Samples and CNB of NSCLC Using an Automated Real-Time PCR System. Annals of Oncology, 2012, 23, ix432.	1.2	O
69	EchoBrush may be superior to standard EUSâ€guided FNA in the evaluation of cystic lesions of the pancreas. Cancer Cytopathology, 2011, 119, 209-214.	2.4	35
70	FDG Uptake and the Diagnostic Yield of Transbronchial Needle Aspiration. Journal of Bronchology and Interventional Pulmonology, 2011, 18, 7-14.	1.4	5
71	Inhibitor of Differentiation-1 as a Novel Prognostic Factor in NSCLC Patients with Adenocarcinoma Histology and Its Potential Contribution to Therapy Resistance. Clinical Cancer Research, 2011, 17, 4155-4166.	7.0	47
72	Assessment of Epidermal Growth Factor Receptor and K-Ras Mutation Status in Cytological Stained Smears of Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcomes. Oncologist, 2011, 16, 877-885.	3.7	75

#	Article	lF	CITATIONS
7 3	Abstract 2251: High VEGFA pathway expression predicts good prognosis in stage I squamous cell carcinoma of the lung. , $2011, \dots$		O
74	Abstract 2219: Inhibitor of differentiation-1 is a novel prognostic factor among NSCLC patients with adenocarcinoma histology and contributes to therapy resistance. , 2011, , .		O
7 5	Feasability and reliabity of the assessment of BRAF and c-KIT mutations in cytologic samples from metastatic melanoma Journal of Clinical Oncology, 2011, 29, 8575-8575.	1.6	O
76	Diagnostic Yield of Electromagnetic Navigation Bronchoscopy Is Highly Dependent on the Presence of a Bronchus Sign on CT Imaging. Chest, 2010, 138, 1316-1321.	0.8	214
77	Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer. BMC Genomics, 2010, 11, 352.	2.8	25
78	Complement Factor H Is Elevated in Bronchoalveolar Lavage Fluid and Sputum from Patients with Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2665-2672.	2. 5	27
79	TGFBI expression is associated with a better response to chemotherapy in NSCLC. Molecular Cancer, 2010, 9, 130.	19.2	61
80	Intraductal papillary mucinous neoplasms (IPMN) of the pancreas: clinico-pathologic results. Revista Espanola De Enfermedades Digestivas, 2010, 102, 314-20.	0.3	3
81	Solid pseudopapillary tumor of the pancreas (SPPT): Still an unsolved enigma. Revista Espanola De Enfermedades Digestivas, 2010, 102, 722-8.	0.3	13
82	Inhibitor of differentiation-1 (Id1): A novel prognostic and predictive factor in lung adenocarcinoma (AC) Journal of Clinical Oncology, 2010, 28, 10611-10611.	1.6	0
83	Assessment of epidermal growth factor receptor (EGFR) and K-ras mutation status in cytologic stained smears of non-small cell lung cancer (NSCLC) patients Journal of Clinical Oncology, 2010, 28, 7560-7560.	1.6	1
84	EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. European Respiratory Journal, 2009, 34, 1477-1486.	6.7	15
85	CCR6 regulates EAE pathogenesis by controlling regulatory CD4 ⁺ Tâ€cell recruitment to target tissues. European Journal of Immunology, 2009, 39, 1671-1681.	2.9	114
86	Large Cell Carcinoma of the Lung. Applied Immunohistochemistry and Molecular Morphology, 2009, 17, 383-392.	1.2	57
87	A Histological Study of the Barrier Effect of the Physis Against Metaphyseal Osteosarcoma. , 2009, , 71-78.		O
88	InÂVivo Evaluation of a New Embolic Spherical Particle (HepaSphere) in a Kidney Animal Model. CardioVascular and Interventional Radiology, 2008, 31, 367-376.	2.0	51
89	Identification of Importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens. BMC Molecular Biology, 2008, 9, 103.	3.0	40
90	Comparative Study of Four Different Spherical Embolic Particles in an Animal Model: A Morphologic and Histologic Evaluation. Journal of Vascular and Interventional Radiology, 2008, 19, 1625-1638.	0.5	58

#	Article	IF	CITATIONS
91	Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates. Histology and Histopathology, 2008, 23, 33-40.	0.7	16
92	Assessing the Relationship Between Lung Cancer Risk and Emphysema Detected on Low-Dose CT of the Chest. Chest, 2007, 132, 1932-1938.	0.8	385
93	Women's Susceptibility to Tobacco Carcinogens and Survival After Diagnosis of Lung Cancer. JAMA - Journal of the American Medical Association, 2006, 296, 180-184.	7.4	220
94	Molecular Profiling of Computed Tomography Screen-Detected Lung Nodules Shows Multiple Malignant Features. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 373-380.	2.5	17
95	Early Lung Cancer Detection Using Spiral Computed Tomography and Positron Emission Tomography. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1378-1383.	5.6	163
96	Mitogen-Activated Protein Kinase Phosphatase-1 Is Overexpressed in Non-Small Cell Lung Cancer and Is an Independent Predictor of Outcome in Patients. Clinical Cancer Research, 2004, 10, 3639-3649.	7.0	125
97	αCP-4, Encoded by a Putative Tumor Suppressor Gene at 3p21, But Not Its Alternative Splice Variant αCP-4a, Is Underexpressed in Lung Cancer. Cancer Research, 2004, 64, 4171-4179.	0.9	27
98	Fine-needle aspiration cytology and immunocytochemistry in the diagnosis of 24 gastrointestinal stromal tumors: A quick, reliable diagnostic method. Diagnostic Cytopathology, 2003, 28, 131-135.	1.0	29
99	Altered patterns of expression of members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung cancer. Lung Cancer, 2003, 41, 131-143.	2.0	138
100	Angiomyolipoma and PEComa Are Immunoreactive for MyoD1 in Cell Cytoplasmic Staining Pattern. Applied Immunohistochemistry and Molecular Morphology, 2003, 11, 156-160.	1.2	24
101	Immunocytochemistry in the differential diagnosis of serous effusions. Cancer, 2001, 93, 68-72.	4.1	69
102	Immunocytochemistry in the differential diagnosis of serous effusions. Cancer, 2001, 93, 68-72.	4.1	0
103	Predicting Metastatic Risk of Gastrointestinal Stromal Tumors: Role of Cell Proliferation and Cell Cycle Regulatory Proteins. International Journal of Surgical Pathology, 2000, 8, 133-144.	0.8	68